litlas
ログインアカウント作成

Mark A. Socinski

1984–2025 年に発表

別表記
Mark A Socinski
126
論文数
30,338
被引用数
85
h 指数
124
i10 指数

被引用数

Mark A. Socinski の年別被引用数1983 年: 被引用 1 件1989 年: 被引用 13 件1990 年: 被引用 17 件1991 年: 被引用 13 件1992 年: 被引用 16 件1993 年: 被引用 12 件1994 年: 被引用 5 件1995 年: 被引用 9 件1996 年: 被引用 1 件1997 年: 被引用 2 件1998 年: 被引用 3 件1999 年: 被引用 4 件2000 年: 被引用 1 件2001 年: 被引用 3 件2002 年: 被引用 6 件2003 年: 被引用 24 件2004 年: 被引用 18 件2005 年: 被引用 31 件2006 年: 被引用 32 件2007 年: 被引用 70 件2008 年: 被引用 91 件2009 年: 被引用 117 件2010 年: 被引用 136 件2011 年: 被引用 149 件2012 年: 被引用 131 件2013 年: 被引用 180 件2014 年: 被引用 150 件2015 年: 被引用 220 件2016 年: 被引用 217 件2017 年: 被引用 273 件2018 年: 被引用 392 件2019 年: 被引用 1,288 件2020 年: 被引用 1,517 件2021 年: 被引用 1,363 件2022 年: 被引用 1,118 件2023 年: 被引用 837 件2024 年: 被引用 1,252 件2025 年: 被引用 549 件2026 年: 被引用 6 件1984〜1988 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,276 件、この内訳の 23.8%中国: 引用元論文 2,081 件、この内訳の 15.1%イタリア: 引用元論文 739 件、この内訳の 5.4%日本: 引用元論文 729 件、この内訳の 5.3%イギリス: 引用元論文 650 件、この内訳の 4.7%フランス: 引用元論文 644 件、この内訳の 4.7%ドイツ: 引用元論文 601 件、この内訳の 4.4%スペイン: 引用元論文 512 件、この内訳の 3.7%カナダ: 引用元論文 416 件、この内訳の 3%韓国: 引用元論文 354 件、この内訳の 2.6%オランダ: 引用元論文 347 件、この内訳の 2.5%スイス: 引用元論文 331 件、この内訳の 2.4%
0%23.8%その他 22.4%

機関

分野

  • Medicine76.8%
  • Biochemistry, Genetics and Molecular Biology14.9%
  • Immunology and Microbiology3.4%
  • Materials Science1.2%
  • Engineering0.9%
  • Computer Science0.8%
  • その他2%

トピック

  • Lung Cancer Treatments and Mutations13.8%
  • Cancer Immunotherapy and Biomarkers12.9%
  • Lung Cancer Research Studies8%
  • Lung Cancer Diagnosis and Treatment5.8%
  • Cancer Genomics and Diagnostics4%
  • Immunotherapy and Immune Responses2.9%
  • その他52.6%

共著者

全論文

検索で開く
  1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    著者: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck - New England Journal of Medicine 2018 被引用: 3,753

  2. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    著者: David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski - New England Journal of Medicine 2017 被引用: 2,575

  3. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

    著者: Mark A. Socinski, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Shengchun Kong, Anthony Lee, Shelley Coleman, Wei Zou, Mark L. McCleland, Geetha Shankar, Martin Reck - Journal of Thoracic Oncology 2021 被引用: 523

  4. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

    著者: Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski, Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski - The Lancet Respiratory Medicine 2019 被引用: 939

  5. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

    著者: Makoto Nishio, Fabrice Barlési, Howard West, S. Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome H. Goldschmidt, Silvia Novello, Francesco Orlandi, Rachel E. Sanborn, Zsuzsanna Szalai, G. Ursol, Diana Mendus, Lijia Wang, Xiaohui Wen, Mark L. McCleland, Tien Hoang, See Phan, Mark A. Socinski - Journal of Thoracic Oncology 2020 被引用: 458

  6. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    著者: Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella‐Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Mark A. Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn - JAMA 2014 被引用: 1,744

  7. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

    著者: Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski, Martin Reck, Christian A. Thomas, Federico Cappuzzo, Tony Mok, Gene Grant Finley, Joachim G.J.V. Aerts, Francesco Orlandi, Denis Moro‐Sibilot, Robert M. Jotte, Daniil Stroyakovskiy, Liza C. Villaruz, Delvys Rodríguez‐Abreu, Wan‐Teck Lim, David M. Merritt, Shelley Coleman, Anthony Lee, Geetha Shankar, Wei Yu, Ilze Bāra, Makoto Nishio - Journal of Thoracic Oncology 2021 被引用: 303

  8. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

    著者: Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Kuan-Chieh Huang, Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski - Journal of Thoracic Oncology 2020 被引用: 607

  9. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer

    著者: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Makoto Nishio, Tony Mok, Martin Reck, Gene Grant Finley, Monika Kaul, Wei Yu, Nindhana Paranthaman, Ilze Bāra, Howard West - JAMA Oncology 2023 被引用: 186

  10. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

    著者: Zoe J. Assaf, Wei Zou, Alexander D. Fine, Mark A. Socinski, Amanda Young, Doron Lipson, Jonathan F. Freidin, Mark Kennedy, Eliana Polisecki, Makoto Nishio, David Fabrizio, Geoffrey R. Oxnard, Craig Cummings, Anja Rode, Martin Reck, Namrata S. Patil, Mark Lee, David S. Shames, Katja Schulze - Nature Medicine 2023 被引用: 139

  11. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

    著者: Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M. Shagan, Sylvia Hu, Young Kwang Chae, Ticiana Leal, Jonathan E. Dowell, Michaela L. Tsai, Christopher Dakhil, Philip J. Stella, Yanling Jin, David S. Shames, Erica Schleifman, David Fabrizio, See Phan, Mark A. Socinski - Nature Medicine 2022 被引用: 170

  12. Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

    著者: Xiuning Le, Robin Cornelissen, Marina Chiara Garassino, Jeffrey Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, Gajanan Bhat, François Lebel, John V. Heymach, Mark A. Socinski - Journal of Clinical Oncology 2021 被引用: 154

  13. Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

    著者: Julia Judd, Nagla Abdel Karim, Hina Khan, Abdul Rafeh Naqash, Yasmine Baca, Joanne Xiu, Ari M. VanderWalde, Hirva Mamdani, Luis E. Raez, Misako Nagasaka, Sachin Gopalkrishna Pai, Mark A. Socinski, Jorge J. Nieva, Chul Kim, Antoinette J. Wozniak, Chukwuemeka Ikpeazu, Gilberto de Lima Lopes, Alexander I. Spira, W. Michael Korn, Edward S. Kim, Stephen V. Liu, Hossein Borghaei - Molecular Cancer Therapeutics 2021 被引用: 186

  14. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

    著者: Howard West, Mark L. McCleland, Federico Cappuzzo, Martin Reck, Tony Mok, Robert M. Jotte, Makoto Nishio, Eugene Kim, Stefanie Morris, Wei Zou, David S. Shames, Meghna Das Thakur, Geetha Shankar, Mark A. Socinski - Journal for ImmunoTherapy of Cancer 2022 被引用: 151

  15. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

    著者: Charles Butts, Mark A. Socinski, Paul Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor–Eliade Ciuleanu, Lionel Bosquée, José Trigo, Alexander I. Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, José Rodrigues Pereira, Wilfried Eberhardt, Christoph Helwig, Andreas Schröder, Frances A. Shepherd - The Lancet Oncology 2013 被引用: 526

  16. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

    著者: David Planchard, Tae Min Kim, Julien Mazières, Élisabeth Quoix, Gregory J. Riely, Fabrice Barlési, Pierre‐Jean Souquet, Egbert F. Smit, Harry J.M. Groen, Ronan J. Kelly, Byoung Chul Cho, Mark A. Socinski, Lini Pandite, Christine Nase, Bo Ma, Anthony M. D’Amelio, Bijoyesh Mookerjee, C. Martin Curtis, Bruce E. Johnson - The Lancet Oncology 2016 被引用: 444

  17. Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

    著者: Kyle Wang, Michael J. Eblan, Allison M. Deal, Matthew B. Lipner, Timothy M. Zagar, Yue Wang, Panayiotis Mavroidis, Carrie B. Lee, Brian C. Jensen, Julian Rosenman, Mark A. Socinski, Thomas E. Stinchcombe, Lawrence B. Marks - Journal of Clinical Oncology 2017 被引用: 427

  18. Crizotinib in Patients With MET-Amplified NSCLC

    著者: D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark, Sai‐Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I. Shapiro, Mark A. Socinski, Danielle Murphy, Umberto Conte, Yiyun Tang, Sherry Wang, Keith D. Wilner, Liza C. Villaruz - Journal of Thoracic Oncology 2021 被引用: 168

  19. Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

    著者: Mark A. Socinski, Igor Bondarenko, Nina Karaseva, Anatoly Makhson, Igor Vynnychenko, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Paul Bhar, Hui Zhang, J. L. Mesías Iglesias, Markus F. Renschler - Journal of Clinical Oncology 2012 被引用: 754

  20. Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

    著者: Joachim von Pawel, Robert M. Jotte, David R. Spigel, Mary O’Brien, Mark A. Socinski, J. Mezger, Martin Steins, Leon Bosquée, Jeffrey A. Bubis, Kristiaan Nackaerts, José Trigo, Philip Clingan, Wolfgang Schütte, Paul Lorigan, Martin Reck, Manuel Dómine, Frances A. Shepherd, Shaoyi Li, Markus F. Renschler - Journal of Clinical Oncology 2014 被引用: 344

  21. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

    著者: Mark A. Socinski, Coleman K. Obasaju, David R. Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Heather A. Wakelee, Nick Thatcher - Journal of Thoracic Oncology 2017 被引用: 243

  22. Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)

    著者: Robin Cornelissen, Arsela Prelaj, Sophie Sun, Christina S. Baik, Mirjana Wollner, Eric B. Haura, Hirva Mamdani, Jonathan W. Riess, Federico Cappuzzo, Marina Chiara Garassino, John V. Heymach, Mark A. Socinski, Szu‐Yun Leu, Gajanan Bhat, François Lebel, Xiuning Le - Journal of Thoracic Oncology 2023 被引用: 55

  23. Clinicopathologic Features of Advanced Squamous NSCLC

    著者: Mark A. Socinski, Coleman K. Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Thomas E. Stinchcombe, Heather A. Wakelee, Carlos Mayo, Nick Thatcher - Journal of Thoracic Oncology 2016 被引用: 197

  24. Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

    著者: Bruna Pellini, Russell W. Madison, Merrida Childress, Shoshana T. Miller, Ole Gjoerup, Jason Cheng, Richard S.P. Huang, Michael Krainock, Pratyush Gupta, Wei Zou, David S. Shames, Solomon Moshkevich, M. Ballinger, Minetta C. Liu, Amanda Young, Minu K. Srivastava, Geoffrey R. Oxnard, Mark A. Socinski - Clinical Cancer Research 2023 被引用: 45